GCC2-ALK was identified and functionally validated as a constitutively activated fusion in NSCLC. The patient benefited from crizotinib treatment initially and then ceritinib after progression, suggesting GCC2-ALK as a novel therapeutic target for ALK inhibitors. This evidence concerns the gene GCC2 and non-small cell lung carcinoma.